Shield Therapeutics plc
SHIEF News Today: Stay Updated with the Latest Shield Therapeutics plc News in Real Time
Find SHIEF news now at Meyka AI. Stay informed with the latest Shield Therapeutics plc stocks updates, including price news, market analysis, and expert insights.
Jefferies Maintains Buy, PT $45 for Viridian Therapeutics (VRDN) Feb 2026
VRDN analyst rating: Jefferies maintains Buy with $45 PT and Evercore keeps Outperform in Feb 2026
Citigroup upgrades AngloGold Ashanti Plc (AU) to Buy Feb 26, 2026
Citigroup upgrade raises AU analyst rating for AngloGold Ashanti Plc on Feb 26, 2026
KYMR: Kymera Therapeutics Maintained Outperform by RBC Capital Feb 26 2026
RBC Capital maintained KYMR analyst rating at Outperform and raised PT to $108 on Feb 26 2026; implications and Meyka AI grade B+
Barclays Maintains Overweight on C4 Therapeutics (CCCC) Feb 26, 2026
Barclays and Cowen maintain ratings on C4 Therapeutics. Read Feb 26, 2026 CCCC analyst rating and implications
H.C. Wainwright Maintains Buy on United Therapeutics (UTHR) Feb 2026
H.C. Wainwright maintained Buy on United Therapeutics (UTHR) and raised the PT to $600 in Feb 2026 — UTHR analyst rating update
Smurfit Kappa SK3.IR EURONEXT closed EUR 41.44 26 Feb 2026: heavy volume view
SK3.IR stock: Smurfit Kappa closed EUR 41.44 on 26 Feb 2026 with heavy volume and a Meyka AI forecast of +37.86%
FTI.PA TechnipFMC Euronext after-hours €5.91 Feb 2026: most-active, upside seen
After-hours volume spikes on FTI.PA stock at €5.912; analysis covers valuation, news, Meyka AI forecast and trading setup
GUI.DE stock down 14.81% intraday on 26 Feb 2026: Weak US demand drags price lower
GUI.DE stock plunges to €18.40 intraday on 26 Feb 2026 after outlook cut; Meyka AI forecast and grade included
Sarepta Therapeutics CEO Ingram Announces Retirement by Year‑End
Biotech firm Sarepta Therapeutics made headlines recently after its Chief Executive Officer Chuck Ingram announced he will retire by the end of the year. This leadership change has drawn attention from investors, biotech analysts, and the broader stock market as shareholders assess what it means for the company’s future strategy and performance. Sarepta Therapeutics is…